ChartMill · Sep 2, 2026
Doximity (NYSE:DOCS): A Quality Investment with Superior Returns on Capital
Doximity (DOCS) excels as a quality stock: 125% ROIC, no debt, strong cash conversion. See why its fundamentals appeal to long-term investors.
DO
NYSE · DOCS
Doximity, Inc.
Healthcare · Medical - Healthcare Information Services
$24.42
Down-$1.93 (-7.32%)
Updated Sep 9, 2026, 6:29 AM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 8.28B
- P/E ratio
- 32.73
- Dividend yield
- 0.00%
- 52-week range
- $17.15 – $76.51
- Volume
- 3.18M
- Avg. volume
- 1.87M
Price performance
DOCS price history
1M range · 20 trading sessions · Daily adjusted prices
DOCS closed at $24.42 after 20 trading sessions, down 6.47% for the selected period.
- Last close
- $24.42
- Period change
- -6.47%
- Period low
- $24.42
- Period high
- $27.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $25.64 | $25.67 | $24.36 | $24.42 | 3.18M |
| Sep 4, 2026 | $26.77 | $27.03 | $26.31 | $26.35 | 1.98M |
| Sep 3, 2026 | $26.70 | $27.32 | $26.495 | $27.10 | 2.52M |
| Sep 2, 2026 | $26.26 | $27.00 | $26.20 | $26.32 | 1.98M |
| Sep 1, 2026 | $26.33 | $27.03 | $26.21 | $26.35 | 2.03M |
| Aug 31, 2026 | $25.84 | $26.846 | $25.84 | $26.71 | 2.19M |
| Aug 28, 2026 | $25.61 | $26.8683 | $25.33 | $26.73 | 3.29M |
| Aug 27, 2026 | $25.13 | $25.81 | $24.89 | $25.59 | 2.47M |
| Aug 26, 2026 | $24.50 | $25.195 | $24.4812 | $24.74 | 1.89M |
| Aug 25, 2026 | $24.95 | $25.35 | $24.60 | $24.74 | 1.73M |
| Aug 24, 2026 | $25.34 | $26.0829 | $25.10 | $25.30 | 2.87M |
| Aug 21, 2026 | $25.84 | $25.87 | $25.12 | $25.33 | 2.68M |
| Aug 20, 2026 | $25.63 | $26.46 | $25.18 | $25.94 | 2.56M |
| Aug 19, 2026 | $24.95 | $25.915 | $24.81 | $25.75 | 4.9M |
| Aug 18, 2026 | $24.94 | $25.28 | $24.745 | $24.94 | 2.98M |
| Aug 17, 2026 | $24.41 | $24.64 | $23.9505 | $24.52 | 3.45M |
| Aug 14, 2026 | $26.615 | $26.70 | $24.80 | $24.80 | 4.12M |
| Aug 13, 2026 | $24.905 | $26.59 | $24.84 | $26.59 | 5.25M |
| Aug 12, 2026 | $25.61 | $26.24 | $24.70 | $24.99 | 4.96M |
| Aug 11, 2026 | $25.57 | $26.94 | $25.25 | $26.11 | 5.74M |
Latest DOCS news
The latest Smart Investors Daily articles mentioning DOCS.
Stock researchCompany · Overview
DOCS research
Overview
Company profile and research snapshot.
Company profile
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $71.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | Barclays | Equal-Weight | — |
| Aug 13, 2026 | Truist Securities | Hold | — |
| Aug 10, 2026 | Wells Fargo | Underweight | — |
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 1, 2026
3 Reasons to Avoid DOCS and 1 Stock to Buy Instead
Since March 2026, Doximity has been in a holding pattern, posting a small return of 2.8% while floating around $26.41. The stock also fell short of the S&P 500’s 12.1% gain during that period.
Fintel · Aug 28, 2026
Doximity (DOCS) Price Target Increased by 12.72% to 30.32
Yahoo · Aug 27, 2026
1 Software Stock on Our Buy List and 2 Facing Challenges
Software is eating the world, and virtually no business is left untouched by it. Companies bringing it to life have been rewarded with explosive earnings growth, and the upward trend shows no signs of stopping as the industry has posted a 44.6% gain over the past six months, beating the S&P 500 by 32.9 percentage points.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
